Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 8/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 7/20 | 0.53 |
| ▸ | MAPT | P10636 | 6/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.53 |
| ▸ | EGFR | P00533 | 3/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.53 |
| ▸ | NSD2 | O96028 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 5/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.50 |
| ▸ | PABPC1 | P11940 | 3/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.45 |
| ▸ | RAB9A | P51151 | 3/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.41 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.41 |
| ▸ | MAOA | P21397 | 4/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.39 |
| ▸ | PTPRC | P08575 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7771196 | 0.89 | MAOA (0.40) | L3MBTL1ALDH1A1MAPK1MAPTTDP1 | |
| SCHEMBL728510 | 0.84 | MEN1 (0.60) | L3MBTL1ALDH1A1MAPK1MAPTTDP1 | |
| SCHEMBL7122665 | 0.82 | MEN1 (0.54) | L3MBTL1ALDH1A1MAPK1MAPTTDP1 | |
| SCHEMBL2020496 | 0.77 | L3MBTL1 (0.58) | L3MBTL1ALDH1A1MAPK1MAPTTDP1 | |
| SCHEMBL11225143 | 0.77 | ALDH1A1 (0.67) | L3MBTL1ALDH1A1MAPK1MAPTTDP1 | |
| SCHEMBL6550296 | 0.74 | L3MBTL1 (0.50) | L3MBTL1ALDH1A1MAPK1MAPTTDP1 | |
| SCHEMBL7302336 | 0.72 | C5AR1 (0.35) | ALDH1A1LMNACYP3A4TSHR | |
| SCHEMBL11577264 | 0.71 | PABPC1 (0.49) | L3MBTL1ALDH1A1MAPK1MAPTTDP1 | |
| SCHEMBL5696019 | 0.71 | MAPT (0.54) | L3MBTL1ALDH1A1MAPK1MAPTTDP1 | |
| SCHEMBL1478996 | 0.71 | MEN1 (0.48) | L3MBTL1ALDH1A1MAPK1MAPTTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030130272-A1 | Anthracene derivatives as anti-cancer agents | BTG INTERNATIONAL LIMITED (GB) | 2003-07-10 | — | — | US | disclosed |
| EP-1244624-A1 | ANTHRACENE DERIVATIVES AS ANTI-CANCER AGENTS | BTG INTERNATIONAL LIMITED (GB) | 2002-10-02 | — | — | EP | disclosed |
| WO-2001044190-A1 | ANTHRACENE DERIVATIVES AS ANTI-CANCER AGENTS | BTG INTERNATIONAL LIMITED (GB) | 2001-06-21 | — | — | WO | disclosed |
| EP-0450021-B1 | ANTI-CANCER COMPOUNDS | BRITISH TECH GROUP (GB) | 1994-02-02 | — | — | EP | disclosed |
| US-5132327-A | ANTI-CANCER COMPOUNDS | NATIONAL RESEARCH DEVELOPMENT CORPORATION (GB) | 1992-07-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030130272-A1 | Anthracene derivatives as anti-cancer agents | TOP2B, TOP1, TOP2A | L3MBTL1 2430/4885ALDH1A1 3026/4885MAPK1 3848/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.